Bioheart, Inc. Share Price OTC Bulletin Board
Equities
US09062F2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
2023 | U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2023 | U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Sales 2021 | 201K 15.43M | Sales 2022 | 82.05K 6.31M | Capitalization | 3.05M 234M |
---|---|---|---|---|---|
Net income 2021 | -3M -231M | Net income 2022 | -2M -154M | EV / Sales 2021 | 59.5 x |
Net Debt 2021 | 8.93M 686M | Net Debt 2022 | 10.08M 775M | EV / Sales 2022 | 160 x |
P/E ratio 2021 |
-0.84
x | P/E ratio 2022 |
-0.99
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.05% |
Managers | Title | Age | Since |
---|---|---|---|
Miguel Tomás
CEO | Chief Executive Officer | 58 | 31/12/02 |
Mark Borman
CHM | Chairman | 69 | 30/04/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Greg Knutson
BRD | Director/Board Member | 72 | 04/03/17 |
Director/Board Member | 100 | 31/05/03 | |
Mark Borman
CHM | Chairman | 69 | 30/04/09 |
1st Jan change | Capi. | |
---|---|---|
+20.10% | 126B | |
+23.39% | 118B | |
+23.26% | 27.87B | |
-18.32% | 20.95B | |
-15.13% | 16.92B | |
-13.37% | 16.18B | |
+9.96% | 14.84B | |
-46.10% | 14.79B | |
+52.04% | 14.08B |